Kamada Ltd.
KMDAHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 24, 2026
Scan Results
Daily timeframeKamada Ltd. manufactures and sells plasma-derived protein therapeutics. With a market capitalization of $448.4M, it sits in small-cap territory. Its products include KAMRAB/KEDRAB indicated as prophylaxis of rabies; CYTOGAM for prophylaxis of Cytomegalovirus disease in kidney, lung, liver, pancreas, heart, and heart/lung transplants; VARIZIG for post exposure prophylaxis of varicella; WINRHO SDF for immune thrombocytopenic purpura and suppression of rhesus isoimmunization; HEPAGAM B for prevention of hepatitis B recurrence liver transplants and post-exposure prophylaxis; GLASSIA for intravenous AATD; KAMRHO (D) IM for prophylaxis of hemolytic disease of newborns; and Echis coloratus and Vipera palaestinae Antiserum to treat snake bite.
Market Cap
$448.4M
Beta
0.13
P/E (TTM)
20.45
P/E (Fwd)
13.47
EPS (TTM)
$0.38
EPS (Fwd)
$0.58
ROE
8.4%
ROA
4.6%
Cash
$70.1M
Total Debt
$11.8M
Free CF
$15.5M
52W Change
13.1%
Annual Financials
Cash vs Debt
Where KMDA stands vs its 150-day and 200-day moving averages
As of the October 20, 2026 close, KMDA finished 1.81% below its 150-day moving average ($7.75) and 2.69% below its 200-day moving average ($7.82). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is KMDA overbought or oversold?
At the October 20, 2026 close, KMDA's RSI(14) was 29.0, in oversold territory (below 30). The MACD histogram was negative, so short-term momentum leaned bearish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
With $70.1M in cash and $11.8M in debt, KMDA maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating. Free cash flow comes in at $15.5M, providing flexibility for reinvestment, buybacks, or dividends. Consistent free cash flow generation is often considered a sign of operational health. ROE of 8.4% points to decent capital efficiency, indicating how much profit the company produces per dollar of shareholder equity. ROA of 4.6% is on the lower side, which is common in asset-heavy industries. Revenue has grown from $129.3M (2022) to $180.5M (2025), reflecting a 40% increase over the period.
The relatively low beta of 0.13 suggests KMDA is a less volatile holding compared to the broader index. With cash comfortably exceeding debt, KMDA has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing KMDA's risk profile alongside its fundamentals and technical indicators provides a more complete picture.